Research study Program year 2022 Source: CMS Open Payments

Assessment of Safety, Tolerability, and Efficacy Measured By Amyloid Reduction of Ly3372993 in Early Symptomatic Alzheimer's Disease

ClinicalTrials.gov NCT05463731

Research payments

$1,334,255

4 payments

Through program year 2022, $1,334,255 in research payments was reported against Assessment of Safety, Tolerability, and Efficacy Measured By Amyloid Reduction of Ly3372993 in Early Symptomatic Alzheimer's Disease, across 4 payments, paid by Eli Lilly and Company.

Paid by: Eli Lilly and Company
ClinicalTrials.gov: NCT05463731

By program year

1 row

Year	Kind	Amount	Payments
2022	Research	$1,334,255	4

Breakdown

Who paid Research payments · program year 2022

Eli Lilly and Company $1,334,255 4 payments

Who received the money Research payments · program year 2022

Optimus U Organisation paid for research $542,521 1 payment
Care Access Research LLC Organisation paid for research $461,479 1 payment
Northwest Clinical Research Center Organisation paid for research $260,054 1 payment
Alpine Clinical Research Center INC Organisation paid for research $70,201 1 payment

Usually the institution or organisation running the study, not a person.

Records

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

Principal investigators named

4 shown

Named on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.

What you are looking at

Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.